A new study suggests that HIV patients with a higher level of a particular biomarker may respond more favourably to an experimental immune activating vaccine

New Research Finds a Way to Predict Which HIV Patients Will Respond Better to Future Therapeutic Vaccine

A new study suggests that HIV patients with a higher level of a particular biomarker may respond more favourably to an experimental¬†immune activating vaccine Researchers at St George‚Äôs, University of London and Norwegian vaccine company Bionor believe the findings might lead to a customised vaccine for certain patients, which might permit them to come off antiretroviral drugs used to treat …